Related Experiment Video

Updated: Sep 26, 2025

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.8K

Eribulin Mesylate Improves Cisplatin-Induced Cytotoxicity of Triple-Negative Breast Cancer by Extracellular

Hyemi Ko1,2, Myungsun Lee2, Eunyoung Cha2

  • 1Department of Surgery, Chungnam National University Hospital, Jung-gu, Daejeon 35015, Korea.

Medicina (Kaunas, Lithuania)
|April 23, 2022
PubMed

Insights

Eribulin combined with cisplatin enhances anti-cancer effects against triple-negative breast cancer (TNBC) by increasing cell death and activating ERK1/2 signaling. This combination therapy offers a promising strategy for TNBC treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Triple-negative breast cancer (TNBC) presents a significant clinical challenge due to its aggressive nature and limited therapeutic options.
  • There is an urgent need for novel and effective treatment strategies to improve patient outcomes in TNBC.

Purpose of the Study:

  • To investigate the synergistic effects of eribulin and cisplatin on triple-negative breast cancer (TNBC) cells.
  • To determine the role of ERK1/2 activation in the combined cytotoxic and apoptotic response induced by eribulin and cisplatin in TNBC.

Main Methods:

  • Assessed cell viability and apoptosis in human breast cancer cell lines (HCC38, MDA-MB-231, SKBR3) treated with eribulin, cisplatin, or their combination.
  • Quantified PARP cleavage and caspase-3 activity to evaluate apoptosis induction.
  • Measured ERK1/2 activation and assessed the impact of the ERK1/2 inhibitor PD98059 on cell viability.

Main Results:

  • Cisplatin significantly reduced cell viability and induced apoptosis across all tested breast cancer cell lines.
  • The combination of eribulin and cisplatin demonstrated significantly lower TNBC cell viability and enhanced apoptosis compared to cisplatin alone.
  • Combined treatment synergistically activated ERK1/2 signaling in TNBC cells, and inhibiting ERK1/2 partially reversed the enhanced cytotoxicity.

Conclusions:

  • Eribulin potentiates the cytotoxic and apoptotic effects of cisplatin in triple-negative breast cancer (TNBC).
  • The synergistic anti-cancer activity of the eribulin-cisplatin combination is associated with increased ERK1/2 activation.
  • This combination therapy represents a promising approach for enhancing treatment efficacy against TNBC.
Keywords:
ERKcisplatineribulintriple-negative breast cancer

More Related Videos

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

8.8K
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.8K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.1K
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
2.3K